Dry Eye Syndrome: Clinical Trials

30 trials for Dry Eye Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 2 unknown. 30 Phase 2, 5 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 230Completed 28, Unknown 2
Phase 15Completed 4, Unknown 1
Phase 35Completed 5

Follow Dry Eye Syndrome: new trials by email Literature Review of Dry Eye Syndrome trials Research Report on Dry Eye Syndrome

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Probiotic in Dry Eye Syndromes
Ophthalmic Probiotic, Opthalmic Placebo, Oral Probiotic Capsule - Dry Eye Syndrome
Phase 2CompletedShiraz University of Medical Sciences402021-07-012023-03-27
Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study
Pro-ocular™ Topical Gel, Placebo Topical Gel - Dry Eye Syndrome, Keratoconjunctivitis Sicca
Phase 2UnknownPharmaDax Inc.802021-05-202021-05-14
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
AGN-242428, AGN-231868, AGN-242428 Vehicle - Dry Eye Disease, Dry Eye Syndrome
Phase 1 / Phase 2CompletedAbbVie2922020-03-042025-05-20
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
BRM421, Placebo - Dry Eye Syndrome
Phase 2 / Phase 3CompletedBRIM Biotechnology Inc.2202020-01-152026-05-01
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca
Phase 2 / Phase 3CompletedAurinia Pharmaceuticals Inc.5082019-10-142021-12-10
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
SJP-0132, Placebo - Dry Eye Disease, Dry Eye Syndrome
Phase 1 / Phase 2CompletedSenju Pharmaceutical Co., Ltd.892019-10-052023-04-20
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle - Dry Eye Syndrome
Phase 2CompletedDompé Farmaceutici S.p.A2612019-06-102024-04-19
Study of TOP1630 for Dry Eye Syndrome
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU - Dry Eye Syndrome
Phase 2 / Phase 3CompletedTopivert Pharma Ltd2022019-02-132019-08-07
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution - Dry Eye Syndrome
Phase 2CompletedAldeyra Therapeutics, Inc.3002018-01-022025-02-06
Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.
SA001 Low dose, SA001 Mid dose, SA001 High dose - Dry Eye Syndrome
Phase 2CompletedSamjin Pharmaceutical Co., Ltd.1722017-11-082022-03-18
Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
AVX012 Ophthalmic Solution Low dose, AVX012 Ophthalmic Solution High dose, Placebo (vehicle) - Dry Eye Syndrome
Phase 1 / Phase 2UnknownAvizorex Pharma, S.L.1722017-04-032018-10-01
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution - Dry Eye Syndrome
Phase 2CompletedORA, Inc.692017-02-202024-02-14
Safety and Efficacy of BRM421 for Dry Eye Syndrome
BRM421, Placebo - Dry Eye Syndrome
Phase 2CompletedBRIM Biotechnology Inc.1572017-02-072026-05-01
Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome
HU00701, HU007, Restasis - Dry Eye Syndrome
Phase 2CompletedHuons Co., Ltd.1142016-03-012018-04-12
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
RGN-259, Placebo - Dry Eye Syndrome
Phase 2 / Phase 3CompletedReGenTree, LLC3172015-09-012019-10-17
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome
Phase 2CompletedSylentis, S.A.662015-06-012016-04-05
Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye
cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution - Dry Eye Syndrome
Phase 2CompletedHerantis Pharma Plc.1612014-12-012015-09-09
Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
rhNGF 20 µg/mL, rhNGF 4 µg/mL - Dry Eye Syndrome
Phase 2CompletedDompé Farmaceutici S.p.A402014-01-202024-04-19
Safety and Efficacy of PG101 for Dry Eye Syndrome
PG101 - Dry Eye Syndrome
Phase 1 / Phase 2CompletedRhodes Pharmaceuticals, L.P.722013-12-012014-03-05
Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome
Phase 1 / Phase 2CompletedSylentis, S.A.602012-11-012015-05-25

Showing 20 of 30. Sign in to see all of them.

Narrower conditions

Dry Eye Syndromes (30)  ·  Keratoconjunctivitis Sicca (4)  ·  Eye Pain (2)

Broader conditions

Eye Diseases (30)  ·  Lacrimal Apparatus Diseases (30)  ·  Conjunctival Diseases (4)  ·  Conjunctivitis (4)  ·  Corneal Diseases (4)  ·  Keratitis (4)  ·  Keratoconjunctivitis (4)  ·  Eye Manifestations (2)  ·  Neurologic Manifestations (2)  ·  Pain (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Signs and Symptoms (2)

Interventions

cenegermin (2)  ·  isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (2)  ·  thymosin beta(4) (2)  ·  Cyclosporins (1)  ·  Gels (1)  ·  Ophthalmic Solutions (1)  ·  Probiotics (1)  ·  lifitegrast (1)  ·  recoflavone (1)

Sponsors

BRIM Biotechnology Inc. (2)  ·  Dompé Farmaceutici S.p.A (2)  ·  ReGenTree, LLC (2)  ·  Sylentis, S.A. (2)  ·  AbbVie (1)  ·  Aldeyra Therapeutics, Inc. (1)  ·  Aurinia Pharmaceuticals Inc. (1)  ·  Avizorex Pharma, S.L. (1)  ·  Bausch & Lomb Incorporated (1)  ·  C.T. Development America, Inc. (1)  ·  Dong-A ST Co., Ltd. (1)  ·  Eyegate Pharmaceuticals, Inc. (1)  ·  Gerhard Garhofer (1)  ·  Herantis Pharma Plc. (1)  ·  Huons Co., Ltd. (1)

Countries

United States (16)  ·  South Korea (4)  ·  Spain (3)  ·  Austria (2)  ·  Estonia (1)  ·  Iran (1)  ·  Mexico (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Gail Torkildsen, MD (7)  ·  John Lonsdale, MD (2)  ·  Blair Boehmer, MD (1)  ·  Choun-Ki Joo, M.D.,Ph.D. (1)  ·  David Wirta, MD (1)  ·  Eugene B McLaurin, MD (1)  ·  Flavio Mantelli, MD, PhD (1)  ·  G Torkildsen, MD (1)  ·  Gail Torkildsen, M.D. (1)  ·  Joel Geffin, MD (1)

Results publications

PMID 27893109, PMID 30944103, PMID 33449860, PMID 33450164, PMID 37256485, PMID 39020305, PMID 42704415

NIH funding

2016 (1)